デフォルト表紙
市場調査レポート
商品コード
1356527

非侵襲性がん診断市場レポート:2030年までの動向、予測、競合分析

Non-Invasive Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.08円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

非侵襲性がん診断市場レポート:2030年までの動向、予測、競合分析
出版日: 2023年09月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

非侵襲的がん診断の動向と予測

世界の非侵襲的がん診断市場は、2024年から2030年までのCAGRが6.8%で、2030年までに推定1,992億米ドルに達すると予測されます。この市場の主な促進要因は、慢性がんに対する懸念の高まり、先進的なバイオマーカーに基づく検出方法のイントロダクション、非侵襲的診断検査の使用を促進するための政府の支援イニシアティブです。世界の非侵襲性がん診断市場は、固形がん、血液がん、肺がん、乳がんの各市場におけるビジネスチャンスにより、将来が有望視されています。

非侵襲的がん診断市場洞察

  • Lucintelの予測では、臨床化学は高感度、低コスト、広範囲に利用可能などの様々な利点があるため、予測期間中に最も高い成長が見込まれます。
  • 乳がんは、世界中で乳がん患者が増加しているため、引き続き最大セグメントです。
  • 北米は、医療インフラが整備されていること、がん関連患者が増加していること、主要企業が存在することから、予測期間中に最も高い成長が見込まれます。

本レポートでは、以下の11の主要な質問について回答する:

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か?
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は?
  • Q.3.今後成長が加速すると思われる地域とその理由は?
  • Q.4.市場力学に影響を与える主な要因は何か?市場における主な課題とビジネスリスクは?
  • Q.5.この市場におけるビジネスリスクと競合の脅威は?
  • Q.6.この市場における新たな動向とその理由は?
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか?
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は?
  • Q.9.この市場における主要企業は?主要企業は事業成長のためにどのような戦略的取り組みを進めているのか?
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか?
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか?

目次

第1章 エグゼクティブサマリー

第2章 世界の非侵襲的がん診断市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向(2018~2023年)と予測(2024~2030年)
  • 世界の非浸潤がん診断市場動向(2018~2023年)と予測(2024~2030年)
  • 治療薬別の世界の非侵襲的がん診断市場
    • 固形腫瘍
    • 血液がん
    • 肺がん
    • 乳がん
    • その他
  • 技術別の世界の非侵襲的がん診断市場
    • 臨床化学
    • 免疫化学
    • 分子診断学
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の非浸潤がん診断市場
  • 北米の非侵襲的がん診断市場
  • 欧州の非侵襲的がん診断市場
  • アジア太平洋の非侵襲的がん診断市場
  • その他地域非侵襲的がん診断市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 治療薬による世界の非侵襲的がん診断市場の成長機会
    • 技術による世界の非侵襲的がん診断市場の成長機会
    • 世界の非浸潤がん診断市場地域の成長機会
  • 世界の非侵襲的がん診断市場における新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の非侵襲的がん診断市場の能力拡大
    • 世界の非侵襲的がん診断市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Precision Therapeutics
  • A&G Pharmaceutical
  • Affymetrix
  • AVIVA Biosciences
  • BIOVIEW
  • Laboratory Corporation of America
  • Quest Diagnostics Incorporated Cancer Genetics
  • Digene
  • Gen-Probe
  • IVDiagnostics
目次

Non-Invasive Cancer Diagnostic Trends and Forecast

The future of the global non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets. The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising concerns of chronic cancer, introduction of advanced bio marker based detection methods,and supportive government initiative to promote the use of non-invasive diagnostic test.

A more than 150-page report is developed to help in your business decisions.

Non-Invasive Cancer Diagnostic by Segment

The study includes a forecast for the global non-invasive cancer diagnostic by therapeutics, technology, end use industry, technology, and region.

Non-Invasive Cancer Diagnostic Market by Therapeutics [Shipment Analysis by Value from 2018 to 2030]:

  • Solid Tumors
  • Blood Cancer
  • Lung Cancer
  • Breast Cancer
  • Others

Non-Invasive Cancer Diagnostic Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Clinical Chemistry
  • Immunochemistry
  • Molecular Diagnostics
  • Others

Non-Invasive Cancer Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Non-Invasive Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-invasive cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-invasive cancer diagnostic companies profiled in this report include-

  • Precision Therapeutics
  • A&G Pharmaceutical
  • Affymetrix
  • AVIVA Biosciences
  • BIOVIEW
  • Laboratory Corporation Of America
  • Quest Diagnostics Incorporated Cancer Genetics
  • Digene
  • Gen-Probe
  • IVDiagnostics

Non-Invasive Cancer Diagnostic Market Insights

  • Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.
  • Breast cancer will remain the largest segment due to increasing number of breast cancer patients around the world.
  • North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.

Features of the Global Non-Invasive Cancer Diagnostic Market

  • Market Size Estimates: Non-invasive cancer diagnostic market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Non-invasive cancer diagnostic market size by therapeutics, technology, and region. in terms of value ($B).
  • Regional Analysis: Non-invasive cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different therapeutics, technology, and region.s for the non-invasive cancer diagnostic market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-invasive cancer diagnostic market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the non-invasive cancer diagnostic market size?

Answer: The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030.

Q.2. What is the growth forecast for non-invasive cancer diagnostic market?

Answer: The global non-invasive cancer diagnostic market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the non-invasive cancer diagnostic market?

Answer: The major drivers for this market are rising concerns of chronic cancer, introduction of advanced bio marker based detection methods, and supportive government initiative to promote the use of non-invasive diagnostic test.

Q.4. What are the major segments for non-invasive cancer diagnostic market?

Answer: The future of the non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets.

Q.5. Who are the key non-invasive cancer diagnostic market companies?

Answer: Some of the key non-invasive cancer diagnostic companies are as follows:

  • Precision Therapeutics
  • A&G Pharmaceutical
  • Affymetrix
  • AVIVA Biosciences
  • BIOVIEW
  • Laboratory Corporation of America
  • Quest Diagnostics Incorporated Cancer Genetics
  • Digene
  • Gen-Probe
  • IVDiagnostics

Q.6. Which non-invasive cancer diagnostic market segment will be the largest in future?

Answer: Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.

Q.7. In non-invasive cancer diagnostic market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the non-invasive cancer diagnostic market by therapeutics (solid tumors, blood cancer, lung cancer,breast cancer, and others), technology (clinical chemistry, immunochemistry, molecular diagnostics, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Non-Invasive Cancer Diagnostic Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Non-Invasive Cancer Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Non-Invasive Cancer Diagnostic Market by Therapeutics
    • 3.3.1: Solid Tumors
    • 3.3.2: Blood Cancer
    • 3.3.3: Lung Cancer
    • 3.3.4: Breast Cancer
    • 3.3.5: Others
  • 3.4: Global Non-Invasive Cancer Diagnostic Market by Technology
    • 3.4.1: Clinical Chemistry
    • 3.4.2: Immunochemistry
    • 3.4.3: Molecular Diagnostics
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Non-Invasive Cancer Diagnostic Market by Region
  • 4.2: North American Non-Invasive Cancer Diagnostic Market
    • 4.2.1: North American Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
    • 4.2.2: North American Non-Invasive Cancer Diagnostic Market by Technology:Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
  • 4.3: European Non-Invasive Cancer Diagnostic Market
    • 4.3.1: European Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
    • 4.3.2: European Non-Invasive Cancer Diagnostic Market by Technology: Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
  • 4.4: APAC Non-Invasive Cancer Diagnostic Market
    • 4.4.1: APAC Non-Invasive Cancer Diagnostic Market by Therapeutics :Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
    • 4.4.2: APAC Non-Invasive Cancer Diagnostic Market by Technology:Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others
  • 4.5: ROW Non-Invasive Cancer Diagnostic Market
    • 4.5.1: ROW Non-Invasive Cancer Diagnostic Market by Therapeutics : Solid tumors, Blood cancer, Lung Cancer,Breast Cancer,and Others
    • 4.5.2: ROW Non-Invasive Cancer Diagnostic Market by Technology: Clinical Chemistry, Immunochemistry, Molecular Diagnostics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market by Therapeutics
    • 6.1.2: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market by Technology
    • 6.1.3: Growth Opportunities for the Global Non-Invasive Cancer Diagnostic Market Region
  • 6.2: Emerging Trends in the Global Non-Invasive Cancer Diagnostic Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Non-Invasive Cancer Diagnostic Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Non-Invasive Cancer Diagnostic Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Precision Therapeutics
  • 7.2: A&G Pharmaceutical
  • 7.3: Affymetrix
  • 7.4: AVIVA Biosciences
  • 7.5: BIOVIEW
  • 7.6: Laboratory Corporation of America
  • 7.7: Quest Diagnostics Incorporated Cancer Genetics
  • 7.8: Digene
  • 7.9: Gen-Probe
  • 7.10: IVDiagnostics